Association of denosumab with serum cytokines, chemokines, and bone-related factors in patients with rheumatoid arthritis: A post hoc analysis of a multicentre, open-label, randomised, parallel-group study
Modern Rheumatology · 2024
DOI: 10.1093/mr/roae002 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Modern Rheumatology, 2024. Verfasst von Naoki Iwamoto und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Scienc…. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Denosumab, Cytokines, Antirheumatic Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objectives
To clarify changes in serum cytokines, chemokines, and bone-related factors during denosumab treatment in rheumatoid arthritis (RA) patients.
Methods
This was a post hoc analysis of a multicentre, open-label, randomised, parallel-group study. Patients were randomly assigned to continue treatment with conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) plus receive treatment with denosumab (csDMARDs plus denosumab group) or to continue treatment with csDMARD therapy alone for 12 months. Serum biomarker levels were measured at baseline and at 6 and 12 months.
Results
Baseline and 6-month data from the csDMARDs plus denosumab (n = 22) and csDMARD therapy alone (n = 22) groups were analysed. Statistically significant changes from baseline were seen: Dickkopf-related protein 1 decreased at 6 and 12 months (both groups); osteopontin decreased at 6 months in the csDMARDs plus denosumab group; osteopontin and soluble CD40 ligand increased at 6 and 12 months in the csDMARD therapy alone group; osteocalcin decreased at 6 and 12 months, epidermal growth factor decreased at 12 months, and macrophage-derived chemokine decreased at 6 months in the csDMARDs plus denosumab group; and interferon gamma-induced protein-10 increased at 12 months in the csDMARD therapy alone group.
Conclusions
Denosumab may inhibit bone destruction by suppressing bone-related factors/chemokines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
- Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan.
- Department of Orthopedic Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Zitieren
APA
Iwamoto, N., Sato, S., Furukawa, K., Michitsuji, T., Shiraishi, K., Watanabe, K., Chiba, K., Osaki, M., & Kawakami, A. (2024). Association of denosumab with serum cytokines, chemokines, and bone-related factors in patients with rheumatoid arthritis: A post hoc analysis of a multicentre, open-label, randomised, parallel-group study. Modern Rheumatology. https://doi.org/10.1093/mr/roae002
Vancouver
Iwamoto N, Sato S, Furukawa K, Michitsuji T, Shiraishi K, Watanabe K, et al. Association of denosumab with serum cytokines, chemokines, and bone-related factors in patients with rheumatoid arthritis: A post hoc analysis of a multicentre, open-label, randomised, parallel-group study. Modern Rheumatology. 2024. doi:10.1093/mr/roae002
BibTeX
@article{Iwamoto2024,
author = {Iwamoto, Naoki and Sato, Shuntaro and Furukawa, Kaori and Michitsuji, Toru and Shiraishi, Kazuteru and Watanabe, Kounosuke and Chiba, Ko and Osaki, Makoto and Kawakami, Atsushi},
title = {Association of denosumab with serum cytokines, chemokines, and bone-related factors in patients with rheumatoid arthritis: A post hoc analysis of a multicentre, open-label, randomised, parallel-group study},
journal = {Modern Rheumatology},
year = {2024},
doi = {10.1093/mr/roae002}
}
EUVIMED